ID29187A - Terapi kombinasi alfa internferon-ribavirin untuk memusnahkan hcv-rna yang dapat ditemukan pada pasien-pasien yang mengalami infeksi hepatitis c kronis - Google Patents

Terapi kombinasi alfa internferon-ribavirin untuk memusnahkan hcv-rna yang dapat ditemukan pada pasien-pasien yang mengalami infeksi hepatitis c kronis

Info

Publication number
ID29187A
ID29187A IDW20010844A ID20010844A ID29187A ID 29187 A ID29187 A ID 29187A ID W20010844 A IDW20010844 A ID W20010844A ID 20010844 A ID20010844 A ID 20010844A ID 29187 A ID29187 A ID 29187A
Authority
ID
Indonesia
Prior art keywords
rna
combination therapy
chronic hepatitis
internferon
alfa
Prior art date
Application number
IDW20010844A
Other languages
English (en)
Indonesian (id)
Inventor
Ashit K Ganguly
Jinping Mccormick
Raymond G Lovey
Frank Bennett
Anil K Saksena
Viyyoor M Girijavallabhan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/348,534 external-priority patent/US6277830B1/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of ID29187A publication Critical patent/ID29187A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
IDW20010844A 1998-10-16 1999-10-14 Terapi kombinasi alfa internferon-ribavirin untuk memusnahkan hcv-rna yang dapat ditemukan pada pasien-pasien yang mengalami infeksi hepatitis c kronis ID29187A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17405998A 1998-10-16 1998-10-16
US09/348,534 US6277830B1 (en) 1998-10-16 1999-07-07 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon

Publications (1)

Publication Number Publication Date
ID29187A true ID29187A (id) 2001-08-09

Family

ID=26869824

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010844A ID29187A (id) 1998-10-16 1999-10-14 Terapi kombinasi alfa internferon-ribavirin untuk memusnahkan hcv-rna yang dapat ditemukan pada pasien-pasien yang mengalami infeksi hepatitis c kronis

Country Status (20)

Country Link
EP (1) EP1121369B1 (https=)
JP (1) JP2002527522A (https=)
CN (1) CN1330658A (https=)
AT (1) ATE284408T1 (https=)
AU (1) AU762395B2 (https=)
BR (1) BR9915546A (https=)
CA (1) CA2346447C (https=)
CZ (1) CZ20011130A3 (https=)
DE (1) DE69922529T2 (https=)
ES (1) ES2229820T3 (https=)
HU (1) HUP0200447A2 (https=)
ID (1) ID29187A (https=)
IL (1) IL142423A0 (https=)
NO (1) NO20011789L (https=)
NZ (1) NZ510811A (https=)
PL (1) PL347268A1 (https=)
RU (1) RU2001113268A (https=)
SK (1) SK4742001A3 (https=)
TR (1) TR200101085T2 (https=)
WO (1) WO2000023454A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924270B2 (en) 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
WO2004084796A2 (en) * 2003-03-28 2004-10-07 Pharmasset Ltd. Compounds for the treatment of flaviviridae infections
JP2007501806A (ja) * 2003-08-13 2007-02-01 ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー ウィルス感染を治療する方法
WO2005049065A2 (en) * 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
JP2008540425A (ja) 2005-05-02 2008-11-20 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝可能部分を含む複素環式抗ウイルス性化合物およびその使用
WO2009028575A1 (ja) 2007-08-27 2009-03-05 National University Corporation Nagoya University 血液凝固第vii因子プロモーターの活性化剤及びその利用
WO2009028573A1 (ja) 2007-08-27 2009-03-05 National University Corporation Nagoya University 血液凝固障害におけるリバビリンの利用
WO2011151667A1 (en) 2010-06-02 2011-12-08 Adbula Kurkayev Antiviral compositions
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CA3033867A1 (en) 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
CN107513055B (zh) * 2017-08-11 2018-06-22 广东昊邦医药健康有限责任公司 一种利巴韦林衍生化合物及其药物组合物
CN117355311A (zh) 2022-05-05 2024-01-05 阿卜杜拉·库尔卡耶夫 用于恢复生物体生理过程和细胞的药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1482736A (en) * 1974-03-18 1977-08-10 Icn Pharmaceuticals 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives
US4544741A (en) * 1982-03-29 1985-10-01 Robins Roland K Azole dinucleotide compounds and methods for their production
US4925930A (en) * 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
WO1998021223A1 (en) * 1996-11-12 1998-05-22 Medivir Ab Nucleosides

Also Published As

Publication number Publication date
TR200101085T2 (tr) 2001-08-21
CA2346447A1 (en) 2000-04-27
SK4742001A3 (en) 2001-11-06
AU762395B2 (en) 2003-06-26
CZ20011130A3 (cs) 2001-08-15
CN1330658A (zh) 2002-01-09
WO2000023454A1 (en) 2000-04-27
NO20011789D0 (no) 2001-04-09
ATE284408T1 (de) 2004-12-15
CA2346447C (en) 2006-01-31
DE69922529T2 (de) 2005-12-15
IL142423A0 (en) 2002-03-10
ES2229820T3 (es) 2005-04-16
BR9915546A (pt) 2001-08-14
DE69922529D1 (de) 2005-01-13
HUP0200447A2 (en) 2002-06-29
EP1121369B1 (en) 2004-12-08
AU1197500A (en) 2000-05-08
JP2002527522A (ja) 2002-08-27
PL347268A1 (en) 2002-03-25
NZ510811A (en) 2003-06-30
EP1121369A1 (en) 2001-08-08
RU2001113268A (ru) 2003-09-27
NO20011789L (no) 2001-06-11

Similar Documents

Publication Publication Date Title
ID29187A (id) Terapi kombinasi alfa internferon-ribavirin untuk memusnahkan hcv-rna yang dapat ditemukan pada pasien-pasien yang mengalami infeksi hepatitis c kronis
MY129244A (en) Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection.
MY117781A (en) Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
HK1052878A1 (zh) 利巴传林-聚乙二醇化干扰素α：丙型肝炎病毒的联合治疗
AR021226A1 (es) Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica
NZ309217A (en) Ribavirin and interferon alpha for the treatment of hepatitis C
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
PT880350E (pt) Tratamento de esclerose multipla
DK1039884T3 (da) Fremgangsmåde til forebyggelse og behandling af lammet myocardium
AR022116A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
ECSP993178A (es) Terapia combinatoria con ribarvirina -interferon alfa para erradicar el hcv - rna detectable en aquellos pacientes que presentan infeccion por hepatitis c cronica
DK0671918T3 (da) Præparater indeholdende acyclovir-lignende forbindelser og 2-vinylsubstituerede nucleosidanaloge til behandling af virusinfektioner
ECSP982669A (es) Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica
NO960866D0 (no) Fremgangsmåte til behandling av leversykdom og lignende indikasjoner med vasodilaterende midler
GEP19991514B (en) Method for Treatment with Interferon